Senior Data Analyst

Medline receives FDA warning letter on its heart procedure syringes. April 09, 2026 01:29 PM CDT The Food and Drug Administration has sent a warning letter to Medline Industries over reported issues with syringes used in cardiac procedures and the company could face regulatory action if the issues are not corrected. Staying current is easy with newsletters delivered straight to your inbox.

FDA flags quality system lapses at Medline facility over device risks. Stock score locked: want to see it? Benzinga Rankings give you vital metrics on any stock - anytime. The U.S. Food and Drug Administration has issued a warning letter to Medline Inc. (NASDAQ:MDLN), following an inspection that identified significant quality system violations tied to its cardiovascular device kits, raising concerns about patient safety and regulatory compliance. FDA flags manufacturing and quality system failures. The inspection, conducted between December 1 and December 12, 2025, at Medline's New York facility, found that the company's angiographic control syringes and related components failed to meet current good manufacturing practice standards. The FDA determined the devices were "adulterated" under federal law due to deficiencies in manufacturing controls, quality systems, and compliance with established regulations. CAPA process breakdown raises safety concerns. The letter dated March 25 highlighted Medline's failure to properly implement corrective and preventive action (CAPA) procedures. Despite 221 complaints and 177 medical device reports tied to syringe disconnections, the company's corrective actions - such as scrapping inventory and increasing cleaning frequency - were deemed insufficient relative to the risk. The FDA noted inconsistencies in Medline's risk assessments, particularly where internal analyses flagged severe risks like air embolism, while the company classified the overall risk as low. Complaint trends also remained above established thresholds even after corrective actions were introduced, yet the company did not escalate or reopen investigations as required. Device recall and ongoing investigations. Medline acknowledged the shortcomings, closed the initial CAPA, and initiated new investigations alongside a product removal plan. The company submitted a formal report to the FDA in March 2026 outlining the removal of affected devices. However, regulators flagged gaps in the scope and timeline of these actions, including unclear investigation deadlines and inconsistencies in manufacturing data tied to complaint rates. Medline contamination risks and cleaning deficiencies. The FDA also cited failures in maintaining cleanroom standards, with visible particulate matter found on manufacturing equipment. More than 100 complaints related to foreign material contamination were recorded over two years. While Medline implemented corrective cleaning measures and updated procedures, the FDA said the company did not adequately assess the impact on products already in the market. Further violations involved inadequate design verification processes. The FDA found insufficient documentation supporting testing decisions for device components, raising questions about whether all affected products met required standards. Regulatory risks and next steps. The FDA warned that failure to address these issues could lead to enforcement actions, including fines or product seizures. Medline has been directed to submit a detailed remediation plan within 15 business days and align all corrective actions with updated Quality Management System Regulation requirements that took effect in February 2026. In February, Medline identified electrical safety risks with its Medline Basic Homecare Beds that may lead to fire. MDLN Price Action: Medline shares were up 2.93% at $45.64 at the time of publication on Thursday, according to Benzinga Pro data. Everyone Bought NVIDIA. The Smart Money Is Now Buying What NVIDIA Needs to Run. The chip trade is crowded. Valuations are stretched. The investors who made money on Phase 1 of AI are already repositioning into the one thing every data center depends on: uninterrupted power. Natural gas and nuclear are the only sources that can deliver it at scale - and one small company just landed a deal to power multiple new hyperscale data centers. Posted In:

Medline hit with FDA warning letter over angiographic syringe manufacturing failures. An FDA inspection of Medline's facilities in December 2025 found that the company fell short of certain good manufacturing practice requirements. The US Food and Drug Administration (FDA) has issued a warning to Medline over deficiencies relating to the company's angiographic syringe manufacturing protocols. The warning letter was only just made publicly available and is dated 25 March. Penned by Barbara Marsden, director of the Office of Regulatory Programs and Office of Product Evaluation and Quality at the FDA's Center for Devices and Radiological Health (CDRH), the document communicates findings from a facility inspection to Medline CEO Jim Boyle. Following an inspection of the company's New York manufacturing facility in December 2025, the letter said that the FDA's inspecting agent determined that Medline's NAMIC-branded angiographic control syringes were "adulterated". This means that good manufacturing practice requirements were not adhered to. The New York facility produces both the syringes and associated kits used to inject radiographic contrast media into patients' blood vessels for several heart procedures. Violations identified by the FDA following the inspection included failures by Medline to "establish and maintain" procedures for implementing corrective and preventive action around complaints received about the NAMIC syringes. Medline initiated corrective procedures, attributing syringe connection issues to excess silicone. The FDA noted that Medline's declaration of a low risk to health was inconsistent given the potential for air embolisms. A syringe air embolism occurs when air bubbles enter a vessel, potentially blocking blood flow. "Your firm's corrective actions only included scrapping devices in inventory and increasing the cleaning frequency of the (b)(4) machine to prevent excess silicone from migrating to the luer connector, despite receiving 221 complaints and filing 177 medical device reports (MDRs) for the disconnection of the NAMIC Angiographic Control Syringes from manifolds which impact patients and clinicians," the letter continued. Richard Kalita, senior manager of quality assurance at Medline, responded to the FDA's observations in two letters dated 13 January and 27 February 2026. However, the agency deemed the company's planned response to the observed range of issues as inadequate. "No information was provided on when you anticipate a new investigation will be completed to determine the cause(s) of the disconnections between the syringes and manifolds to assure your actions are timely and commensurate with risk of this issue," Marsden wrote. "Furthermore, no assurance was provided that the scope of the product removal will include affected devices manufactured both before and after the corrective action (April 17, 2024) since the corrective action was found to be ineffective," Marsden continued. Other remediation issues identified by the FDA include Medline's "failure to establish and maintain procedures for verifying the device design" and to "establish and maintain schedules for the adjustment, cleaning, and other maintenance of equipment to ensure that manufacturing specifications are met". From the date of the letter's issuance, the FDA concluded that Medline has 15 days to respond to the warning letter. It must provide "specific steps" it intends to take to address the noted violations and inadequate responses outlined in Kalita's prior correspondence with the agency, as well as an explanation of how the company plans to prevent the same, or similar, violations from occurring again. The FDA's warning letter represents the first major hurdle Medline will have to navigate since going public. The company went public on the Nasdaq stock exchange on 17 December 2025, raising $6.26bn in an upsized initial public offering (IPO) that valued the company at $46bn, making it the largest healthcare IPO in history. Give your business an edge with our leading industry insights.